**Preliminary Clinical Experience With XmAb20717, a PD-1 x CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors**

Elaine Shum, 1 Matthew J. Reilley, 2 Yana G. Najyan, 1 Addi I. Daud, 1 John A. Thompson, 1 Joaquim C. Baranda, 1 R. Donald Harvey, 1 Anthony F. Shields, 2 Ezra E. Cohen, 3 Shubham Patel, 3 Ram S. Leidner, 1 Ali Alia, 2 Roger & Cohen, 1 Barbara Chritsakis, 1 William H. Stein, 1 Steven H. Kershaw, 1 Catherine A. Ellison, 1 Ying Dong, 2 David B. Bigner, 1 Gregory Chiarini, 1 Reema Shroff, 1 Raphael Clynes, 1 Sowmya Chollate, 1 Foong Yuen et al., Nat Med 2020. Human XmAb 20717: a bispecific PD-1 x CTLA-4 monoclonal antibody that non-covalently targets PD-1 and CTLA-4, and shows pharmacodynamic and preclinical efficacy in advanced cancer models.

**BACKGROUND**

- **XmAb20717** is a bispecific PD-1 x CTLA-4 antibody that non-covalently targets PD-1 and CTLA-4, and shows pharmacodynamic and preclinical efficacy in advanced cancer models.

**METHODS**

- This was a phase 1 dose escalation study of XmAb20717 in patients with pretreated advanced solid tumors.
- **Dose Escalation:**
  - Dose levels were 0.1, 0.3, 1, 3, 10, and 30 mg/kg.
  - **Cohort sizes:**
    - 3 patients per cohort.
  - **Randomization:**
    - Randomized to one of 6 dose levels:
      - 0.1 mg/kg (n=3), 0.3 mg/kg (n=3), 1 mg/kg (n=3), 3 mg/kg (n=3), 10 mg/kg (n=3), and 30 mg/kg (n=3).
- **Efficacy endpoints:**
  - **Progression-free Survival (PFS):**
    - 
  - **Safety/TOLE: Tolerability, biomarker, lab changes, and PD (RECIST 1.1).

**RESULTS**

- **XmAb20717 Induces Intratumoral T-Cell Activation and Perforin-Mediated killing Consistent With Dual PD-L1/CTLA-4 Blockade**
  - 

**CONCLUSIONS**

- XmAb20717 was generally well tolerated. The most common treatment-related adverse events (TCR) were fatigue, nausea, headache, diarrhea, and conjunctivitis.
- Patients had a history of multiple treatments and a range of comorbidities.
- The most common treatment-related adverse events (TCR) were fatigue, nausea, headache, diarrhea, and conjunctivitis.
- Patients had a history of multiple treatments and a range of comorbidities.